Skip to Content Skip to Content

Perelman School of Medicine

Visit the School's Site
Reset All Filters
2949 Results
Decade-long remission after CAR T cell therapy
Two people stand closely together, smiling

Bill Ludwig, left, was the first patient to receive CAR T cells as part of clinical trials at Abramson Cancer Center. Carl June, right, has played a pioneering roll in the therapeutic use of CAR T cells. (Image: Penn Medicine)

Decade-long remission after CAR T cell therapy

Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.

Caren Begun

Understanding climate stories
Hands working the soil around a new plant

Understanding climate stories

In the latest episode of Penn Today’s “Understand This …” podcast series, Bethany Wiggin of the School of Arts & Sciences and Jennifer Pinto-Martin of the School of Nursing discuss climate stories, climate grief, and climate literacy.
Early discharge of healthy newborns during the pandemic
Parent at home with newborn in their arms.

Early discharge of healthy newborns during the pandemic

In a new study, Sara Handley and colleagues find that a shorter stay did not increase infant readmissions in the first week, suggesting that earlier discharge can be done safely.

From Penn LDI

Ten from Penn elected 2021 AAAS Fellows
Researchers Sara Cherry, Susan Davidson, Douglas Durian, Kathleen Hall Jamieson, Katalin Kariko, I. Joseph Kroll, Mingyao Li, Hongjun Song, Duncan Watts, and E. John Wherry

Penn’s new AAAS Fellows for 2021, clockwise from top left: Sara Cherry, Susan Davidson, Douglas Durian, Kathleen Hall Jamieson, Katalin Karikó, I. Joseph Kroll, Mingyao Li, Hongjun Song, Duncan Watts, and E. John Wherry

Ten from Penn elected 2021 AAAS Fellows

Ten scholars representing five schools across the University of Pennsylvania have been named to the 2021 class of American Association for the Advancement of Science Fellows, recognized for their “scientifically and socially distinguished achievements.”

Katherine Unger Baillie

After the shutdown, what comes next for the former Philadelphia Energy Solutions refinery?
philadelphia refinery

Flames and smoke emerge from the Philadelphia Energy Solutions Refining Complex in Philadelphia, Friday, June 21, 2019. (Image: Matt Rourke/AP Images)

After the shutdown, what comes next for the former Philadelphia Energy Solutions refinery?

Creating a greener, more equitable future at the site means understanding its complex history, its long-running public health impacts, and working in partnership with communities.

Erica K. Brockmeier

Racial disparity in follow-up appointments disappears with telemedicine
A patient having a telemedicine appointment with a doctor via a desktop computer screen.

Racial disparity in follow-up appointments disappears with telemedicine

An inequity in the rate of Black patients making it to their primary care appointment after a hospitalization was eliminated after telemedicine became widely used amid the COVID-19 pandemic.

From Penn Medicine News

Busting myths about the Asian American ‘model minority’
Patient with a face mask looking at a computer with a medical professional.

Busting myths about the Asian American ‘model minority’

Two new studies highlight the problem with aggregating diverse groups of people into a single category of “Asian American” when applied to cardiovascular disease and cancer diagnosis and outcomes.

From Penn LDI

A new method to increase effectiveness of nanomedicines
Microscopic view of nanomedicine particles attacked by immune system proteins.

Upon injection into the blood, nanomedicines (blue spheres) are immediately attacked by proteins of the immune system called complement proteins (orange). Complement proteins cause rapid destruction of the nanomedicine, and also induce an anaphylaxis-like reaction. By attaching complement-degrading proteins (yellow ninjas made of protein) to the surface of nanomedicines, Penn researchers have largely solved this problem, potentially allowing more diseases to be safely treated by nanomedicine.(Image: Penn Medicine News)

A new method to increase effectiveness of nanomedicines

Penn Medicine researchers have developed a new technique that uses complement inhibitor Factor I to prevent proteins from attacking treatment-carrying nanoparticles so they can better reach targets within the body.

Sophie Kluthe

Protein controlled by both light and temperature can inform cell signal pathways
Microscopic view of cells illuminated by light.

Protein controlled by both light and temperature can inform cell signal pathways

Penn Engineering researchers have described a new type of optogenetic protein that can be controlled not only by light, but also by temperature, allowing for a higher degree of control in the manipulation of cellular pathways.

From Penn Engineering Today